GSK commences tender offer to acquire Human Genome Sciences for US $13.00 per share in cash
GlaxoSmithKline plc today announced that it has commenced its previously announced tender offer to acquire all of the outstanding shares of Human Genome Sciences for US$13.00 per share in cash.
The proposed biopharmaceutical facility is part of £500m of investment that GSK expects will create up to 1,000 UK jobs.